Furosemide (Lasix / Salix)

Furosemide is the most widely used loop diuretic in veterinary medicine, employed across multiple species for the management of edematous conditions arising from cardiac insufficiency, renal disease, and other pathological processes that cause abnormal fluid retention. Marketed under the brand names Lasix, Salix, and Disal, furosemide holds FDA approval for use in dogs, cats, horses, and cattle, making it one of the few diuretics with broad species labeling in veterinary pharmacology. The drug's ability to produce rapid, dose-dependent diuresis through its action on the renal tubular system has established it as an indispensable tool in veterinary emergency medicine and chronic disease management alike.

The pharmacological action of furosemide centers on the thick ascending limb of the loop of Henle in the nephron, where it inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter, also designated as NKCC2. This cotransporter is responsible for the reabsorption of approximately 25% of filtered sodium from the tubular fluid back into the blood. By blocking this transporter, furosemide prevents the reabsorption of sodium, potassium, and chloride at this critical nephron segment, resulting in their enhanced excretion in the urine along with obligatory water. The resulting diuresis is substantially more potent than that produced by thiazide diuretics, which act on the distal convoluted tubule where only about 5 to 8% of sodium reabsorption occurs.

Beyond its direct tubular effects, furosemide exerts several additional pharmacological actions that contribute to its clinical utility. The drug increases renal blood flow and causes redistribution of intrarenal blood flow patterns, which may benefit patients with compromised renal perfusion. Furosemide also produces a transient increase in glomerular filtration rate in some circumstances. In the pulmonary vasculature, furosemide causes venodilation that reduces preload on the heart, an effect that precedes the onset of diuresis and provides immediate hemodynamic benefit in patients with acute pulmonary edema. This combination of vascular and renal effects makes furosemide particularly effective in emergency management of life-threatening fluid overload conditions.

In the farm animal context, furosemide serves two primary clinical roles that reflect the distinct physiological challenges of different livestock species. In cattle, the labeled indication is the treatment of physiological parturient edema of the mammary gland and associated structures, a common condition in periparturient dairy cows that can compromise milk quality and udder health. In horses, furosemide is used for the treatment of edema associated with cardiac insufficiency and acute non-inflammatory tissue edema, and it has gained widespread notoriety for its use in managing exercise-induced pulmonary hemorrhage in racehorses, though regulatory approaches to this application vary by jurisdiction.

The FDA-labeled indication for furosemide in cattle is specifically the treatment of physiological parturient edema of the mammary gland and associated structures. Udder edema is an extremely common condition in dairy cattle during the periparturient period, occurring when fluid accumulates in the interstitial tissues of the udder, ventral abdomen, and sometimes the brisket region in the days to weeks surrounding calving. While mild udder edema is considered physiological and self-limiting, severe cases can cause significant discomfort, impede milking, predispose the udder to injury and mastitis, and reduce milk yield. Furosemide provides rapid mobilization of excess interstitial fluid through its potent diuretic action, reducing the swelling and restoring normal udder function.

In horses, furosemide carries labeled indications for the treatment of edema associated with cardiac insufficiency and acute non-inflammatory tissue edema. Congestive heart failure, while less common in horses than in dogs, does occur and can produce pulmonary edema, ventral edema, and pleural effusion that respond to diuretic therapy. Acute non-inflammatory edema in horses can result from a variety of causes including lymphatic obstruction, venous stasis, hypoproteinemia, and traumatic fluid accumulation. Perhaps the most well-known equine application of furosemide is the management of exercise-induced pulmonary hemorrhage (EIPH), commonly referred to as bleeding. EIPH affects the vast majority of racehorses to some degree and can result in epistaxis, impaired athletic performance, and respiratory compromise.

Extra-label uses of furosemide in farm animal species extend beyond the labeled indications and include the management of pulmonary edema from any cause, treatment of acute renal failure where promotion of urine output is therapeutically desirable, reduction of dangerously elevated serum potassium levels (hyperkalemia), management of cerebral edema, and reduction of intracranial pressure in acute neurological emergencies. In cattle, furosemide may be used extra-label for conditions beyond udder edema, such as pulmonary edema resulting from acute bovine respiratory distress syndrome or fluid overload from aggressive intravenous fluid therapy.

The use of furosemide to treat EIPH in racehorses has generated considerable regulatory debate and scientific scrutiny. Approximately three-quarters of racehorses in North America have historically raced with furosemide, administered four hours before competition to reduce pulmonary capillary pressure and decrease the severity of hemorrhage during intense exercise. Evidence suggests that furosemide reduces both the incidence and severity of EIPH, and horses racing on furosemide tend to achieve faster times and higher earnings. However, growing concerns about the drug's performance-enhancing effects unrelated to EIPH, its impact on horse welfare through chronic dehydration and electrolyte depletion, and the desire to promote a drug-free racing environment have led many jurisdictions to restrict or prohibit race-day furosemide use.

Dosing of furosemide varies by species, indication, formulation, and route of administration. In cattle, the labeled dosage for parturient udder edema is 500 mg (10 mL of the 5% injection) administered intramuscularly or intravenously once daily, or 250 mg (5 mL) twice daily at 12-hour intervals. Treatment should not exceed 48 hours postparturition. The veterinarian should evaluate the degree of edema present and adjust the dosage schedule accordingly. This relatively high dose reflects the large body mass of dairy cattle and the substantial volume of edematous tissue that must be dehydrated to achieve clinical improvement.

In horses, the usual parenteral dosage is approximately 0.5 mg per pound of body weight (1.0 mg/kg), administered intravenously or intramuscularly once or twice daily at 6 to 8 hour intervals until the desired diuretic effect is achieved. For a 500 kg horse, this translates to approximately 500 mg or 10 mL of the 50 mg/mL injectable solution. A prompt diuresis usually follows the initial treatment. For EIPH prevention in racehorses, furosemide is typically administered at 250 to 500 mg intravenously approximately four hours before competition, though specific dosing protocols vary by racing jurisdiction. A loading dose of 0.12 mg/kg followed by a constant rate infusion of 0.12 mg/kg per hour has been evaluated and produces more profound diuresis over the first eight hours of treatment.

The route of administration significantly influences the onset, magnitude, and duration of furosemide's diuretic effect. Intravenous administration produces the most rapid onset, with diuresis typically beginning within 5 to 10 minutes and peaking within 30 minutes. The effect generally lasts approximately 2 hours after IV dosing. Intramuscular administration produces a somewhat delayed onset of approximately 15 to 30 minutes, with peak effects at around 1 hour and a duration of approximately 2 to 4 hours. Oral bioavailability of furosemide is variable among species; it is moderate in dogs but poor in horses, which is why parenteral administration is strongly preferred in equine patients. For chronic management, oral furosemide tablets may be appropriate in some species, though the injectable formulation is generally used in farm animal practice.

Mobilization of edema fluid should be approached with clinical judgment regarding the rate and extent of diuresis. Overly aggressive fluid removal can result in dehydration, electrolyte depletion, hypotension, and cardiovascular compromise, particularly in animals that are already hemodynamically unstable. An intermittent dosing strategy, such as administration on alternate days or for 2 to 4 consecutive days per week, may be safer and more effective than continuous daily dosing for chronic conditions. Injectable furosemide therapy should generally not exceed 3 days without transitioning to a carefully programmed maintenance schedule, and the veterinarian should reassess the patient regularly to determine whether continued diuretic therapy is warranted.

The adverse effect profile of furosemide is directly related to its potent diuretic and saluretic activity. The most clinically significant side effects involve electrolyte derangements resulting from the enhanced renal excretion of sodium, potassium, chloride, calcium, magnesium, and hydrogen ions. Hypokalemia (low blood potassium) is the most commonly encountered electrolyte disturbance and can manifest as muscle weakness, ileus, cardiac arrhythmias, and in severe cases, respiratory muscle paralysis. Hypochloremic metabolic alkalosis develops when disproportionate chloride losses exceed bicarbonate excretion, elevating blood pH. These metabolic disturbances are dose-dependent and cumulative, becoming more pronounced with prolonged therapy or aggressive dosing.

Dehydration and hypovolemia represent the expected consequences of excessive or prolonged diuresis and are among the most important adverse effects to monitor. Animals treated with furosemide should have access to fresh drinking water, and fluid intake and output should be monitored wherever practical. Clinical signs of dehydration include decreased skin turgor, sunken eyes, dry mucous membranes, tachycardia, and concentrated urine. In lactating dairy cattle, overzealous diuretic therapy can reduce milk production by depleting the body water pool available for milk synthesis. The clinical goal is to achieve sufficient fluid mobilization to resolve pathological edema without inducing clinically significant dehydration.

Furosemide administration is associated with an increase in blood glucose levels, which is generally not clinically significant in most patients but may be relevant in animals with concurrent diabetes mellitus or other glucose regulatory disorders. Hearing loss (ototoxicity) has been reported, particularly in cats receiving rapid high-dose intravenous administration, and may occur in other species at excessive doses. The ototoxic mechanism involves disruption of the endocochlear potential in the inner ear, which depends on the same Na-K-2Cl cotransporter that furosemide inhibits in the kidney. Concurrent administration of other potentially ototoxic drugs, particularly aminoglycoside antibiotics, increases the risk of hearing damage.

Toxic overdose of furosemide produces an exaggerated version of its pharmacological effects, with massive diuresis leading to severe dehydration, profound electrolyte depletion, cardiovascular collapse, and potentially death. In experimental studies, toxic doses produced convulsions, ataxia, paralysis, and collapse in laboratory animals. Animals surviving toxic overdose may become severely dehydrated and depleted of essential electrolytes. Treatment of furosemide overdose is supportive, focusing on aggressive intravenous fluid therapy with balanced electrolyte solutions and correction of specific electrolyte deficits based on serial blood chemistry monitoring.

Furosemide interacts with numerous other pharmacological agents through both pharmacokinetic and pharmacodynamic mechanisms, and the prescribing veterinarian should be aware of these interactions when designing treatment protocols for farm animals. The most clinically important interaction involves concurrent administration of aminoglycoside antibiotics (gentamicin, amikacin, neomycin), which share furosemide's potential for nephrotoxicity and ototoxicity. The combination of a loop diuretic with an aminoglycoside can produce additive or synergistic damage to both renal tubular cells and cochlear hair cells, and should be avoided whenever possible. If the combination is deemed necessary, meticulous monitoring of renal function and hydration status is essential.

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine, phenylbutazone, and meloxicam can antagonize the diuretic effect of furosemide through their inhibition of prostaglandin synthesis. Renal prostaglandins normally contribute to the maintenance of renal blood flow and the tubular response to loop diuretics, and NSAID-mediated prostaglandin suppression can blunt furosemide's diuretic efficacy and potentially worsen renal function in compromised patients. This interaction is particularly relevant in equine practice, where NSAIDs are frequently co-administered with furosemide in horses with musculoskeletal conditions and concurrent edematous disorders.

Corticosteroids such as dexamethasone and prednisolone can potentiate the potassium-depleting effect of furosemide, increasing the risk of clinically significant hypokalemia when both drug classes are administered concurrently. The combination of corticosteroid-induced potassium wasting with furosemide-induced kaliuresis can produce potassium depletion that exceeds what either drug would cause alone. Patients receiving both agents should have serum potassium levels monitored and may require potassium supplementation. Cardiac glycosides (digoxin), while uncommonly used in farm animal practice, have enhanced toxicity in the setting of hypokalemia, making potassium monitoring essential if furosemide and digoxin are co-administered.

Furosemide is contraindicated in animals with anuria (absence of urine production) that is unresponsive to an initial test dose of the diuretic, as continued administration to an anuric patient increases the risk of toxicity without providing therapeutic benefit. The drug should be used with caution in animals with pre-existing electrolyte imbalances, severe hepatic disease (where diuretic-induced alkalosis can precipitate hepatic encephalopathy), and in dehydrated patients where further fluid loss could be dangerous. In pregnant animals, furosemide crosses the placenta and should be used only when the potential benefit justifies the potential risk to the fetus. The drug is excreted in milk, which is relevant to the established milk withdrawal period in lactating cattle.

Furosemide carries specific withdrawal time requirements for food-producing animals that must be strictly observed to ensure the safety of meat and milk entering the human food supply. For cattle, the labeled meat withdrawal period is 48 hours following the last treatment. Milk taken from treated animals during the treatment period and for 48 hours (four milkings at 12-hour intervals) after the last treatment must not be used for human consumption. These withdrawal periods are based on tissue residue depletion studies that demonstrate the time required for furosemide concentrations in edible tissues and milk to fall below the established tolerances.

For horses, the product labeling states that furosemide should not be used in horses intended for human consumption. This restriction reflects the lack of established tissue residue tolerances for furosemide in equine tissues in jurisdictions where horsemeat may enter the food chain. In the United States, where the slaughter of horses for human consumption has been effectively prohibited through federal funding restrictions on USDA inspection of equine slaughter facilities, this restriction is of limited practical significance for most equine practitioners. However, in countries where horsemeat consumption is practiced, the prohibition on furosemide use in food-producing horses must be observed.

Extra-label use of furosemide in food animal species other than cattle may require extended withdrawal periods established by the prescribing veterinarian in consultation with FARAD or equivalent regulatory resources. When furosemide is used extra-label in sheep, goats, swine, or other food-producing species, no established withdrawal time exists, and the veterinarian must determine an appropriate withdrawal period based on pharmacokinetic data, the dose administered, and the available residue information. Conservative withdrawal periods are warranted in extra-label situations to ensure complete elimination of drug residues from edible tissues.

Producers and veterinarians must maintain complete treatment records for all furosemide administered to food-producing animals, including the identity of treated animals, dates of treatment, doses administered, routes of administration, and the withdrawal dates for both meat and milk. These records are essential for regulatory compliance and traceability in the food safety system. Milk from treated cattle must be properly disposed of during the withdrawal period and must not be commingled with saleable milk. Similarly, treated animals must not be marketed for slaughter until the prescribed withdrawal period has elapsed.

In dairy cattle, parturient udder edema remains the most common clinical application of furosemide in farm animal practice. The condition develops during the final weeks of gestation and the early postpartum period, driven by hormonal changes, increased blood flow to the mammary gland, elevated venous pressure from the gravid uterus, and changes in capillary permeability that promote fluid transudation into interstitial tissues. While first-calf heifers are most commonly and severely affected, the condition can occur in multiparous cows as well. Severe udder edema extends beyond the udder itself to involve the ventral abdomen, brisket, and even the perineal region, causing significant discomfort and difficulty in milk letdown and machine milking.

Furosemide treatment for udder edema produces measurable reduction in udder swelling within hours of administration, improving animal comfort and facilitating milking. However, diuretic therapy addresses the symptom rather than the underlying physiological process, and some degree of recurrence is expected as long as the hormonal and hemodynamic conditions that promote edema formation persist. For this reason, treatment duration is limited to 48 hours postparturition, after which the physiological edema typically begins to resolve spontaneously. Adjunctive management measures include frequent milking, udder massage, support wraps or udder slings, reduced dietary salt and potassium in the prepartum ration, and exercise to promote venous and lymphatic drainage.

In horses, furosemide's role in managing exercise-induced pulmonary hemorrhage represents its most controversial and extensively studied application. EIPH occurs when the extreme pulmonary capillary pressures generated during maximal exercise cause rupture of the thin alveolar-capillary membrane, resulting in hemorrhage into the airways. The condition affects virtually all racehorses to some degree, with endoscopic evidence of blood in the trachea detectable in approximately 75 to 100% of horses after intense exercise. Furosemide reduces EIPH severity through its diuretic-mediated reduction in blood volume and cardiac filling pressures, which lowers the transmural pressure gradient across the pulmonary capillary wall during exercise.

Beyond EIPH and udder edema, furosemide finds application in emergency veterinary medicine across farm animal species for the acute management of pulmonary edema from any cause, including aspiration, toxic exposure, anaphylaxis, and cardiogenic shock. The drug's rapid onset of action when administered intravenously makes it a first-line intervention for life-threatening fluid accumulation in the lungs, where even minutes of delay can prove fatal. In these emergency scenarios, the diuretic effect works in concert with furosemide's acute venodilatory action, which immediately reduces pulmonary venous pressure and transudation of fluid into the alveolar space before the diuretic effect on urine output begins.

The molecular target of furosemide is the sodium-potassium-2 chloride cotransporter (NKCC2) located on the luminal membrane of epithelial cells in the thick ascending limb of the loop of Henle. This transporter normally mediates the electroneutral reabsorption of one sodium ion, one potassium ion, and two chloride ions from the tubular fluid, driven by the low intracellular sodium concentration maintained by the basolateral sodium-potassium ATPase. Furosemide binds to the chloride binding site on the NKCC2 transporter, competitively inhibiting its function and preventing the reabsorption of these ions. Because the thick ascending limb normally reabsorbs approximately 25% of the filtered sodium load, blockade of this segment produces substantially greater natriuresis than inhibition of more distal nephron segments.

The consequences of NKCC2 inhibition extend beyond simple sodium and water diuresis to encompass a complex array of electrolyte and acid-base effects. By blocking potassium reabsorption at the thick ascending limb and simultaneously increasing sodium delivery to the distal nephron and collecting duct, furosemide promotes potassium secretion through sodium-potassium exchange mechanisms in the principal cells of the collecting duct. This dual effect accounts for the significant kaliuretic (potassium-wasting) activity of loop diuretics. Enhanced hydrogen ion secretion without proportional bicarbonate excretion produces a metabolic alkalosis that can become clinically significant with prolonged therapy. Calcium and magnesium excretion are also increased, as the thick ascending limb is a major site of divalent cation reabsorption.

The disruption of the medullary concentration gradient represents another important consequence of furosemide's action in the thick ascending limb. Under normal conditions, the active reabsorption of sodium and chloride in this water-impermeable segment generates the hyperosmotic medullary interstitium that drives water reabsorption from the collecting ducts under the influence of antidiuretic hormone. By inhibiting solute reabsorption in the thick ascending limb, furosemide reduces the osmolarity of the medullary interstitium, impairing the kidney's ability to concentrate urine even in the presence of adequate antidiuretic hormone. This impairment of concentrating ability contributes to the production of large volumes of dilute urine characteristic of loop diuretic therapy.

Furosemide's pharmacokinetic properties vary among species and influence clinical dosing strategies. The drug is highly protein-bound in plasma (approximately 95% or greater) and reaches the tubular lumen primarily through active secretion by the organic anion transport system in the proximal tubule rather than through glomerular filtration. This secretory mechanism explains why furosemide's diuretic effect correlates with its urinary concentration rather than its plasma concentration. Conditions that impair proximal tubular secretion, such as uremia, hypoalbuminemia, or competition from other organic anions, can reduce furosemide delivery to its site of action and diminish its diuretic efficacy. The elimination half-life is relatively short across species, which necessitates repeated dosing for sustained diuretic effect.

Furosemide injectable solution should be stored at controlled room temperature between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit) and must be protected from light to prevent photodegradation. Exposure to light causes furosemide to undergo photolytic decomposition, which is visible as a yellowing of the normally colorless to pale yellow solution. Parenteral formulations that have developed a distinctly yellow discoloration have degraded and should not be used, as the decomposition products may be less effective and potentially irritating. Similarly, furosemide tablets that have been exposed to excessive light may become discolored and should be discarded.

The injectable formulation is compatible with normal saline (0.9% sodium chloride) and lactated Ringer's solution for dilution or intravenous infusion. However, furosemide is alkaline in pH and is incompatible with many acidic solutions and other drugs in the same syringe or infusion line. Mixing furosemide with acidic solutions can cause precipitation of the drug. When administering furosemide through an intravenous line, the line should be flushed before and after administration if other drugs are being delivered through the same catheter. The multidose vials (50 mL for dogs, cats, horses, and cattle; 100 mL for horses and cattle) should be handled with aseptic technique to prevent bacterial contamination of the solution.

Practical considerations for field use in farm animal practice include the importance of accurate dosing, particularly in cattle where the large body mass requires relatively large volumes of injectable solution. A 600 kg dairy cow receiving the labeled dose of 500 mg would require 10 mL of the 50 mg/mL formulation, which is a manageable volume for intramuscular or intravenous injection. However, practitioners should be prepared for the rapid onset of copious urination that follows intravenous administration, as this can be disruptive during examination or treatment procedures. Timing of administration should account for the predictable urinary output that will follow.

Monitoring recommendations for animals receiving furosemide include assessment of hydration status, body weight when practical, serum electrolytes (particularly potassium, sodium, and chloride), blood urea nitrogen, creatinine, and acid-base status for animals on prolonged therapy. In the emergency setting, monitoring should be intensive with frequent reassessment of respiratory rate and effort, heart rate and rhythm, mucous membrane color, and capillary refill time. For dairy cattle receiving furosemide for udder edema, monitoring should include evaluation of udder size and consistency, ease of milking, and milk quality. The short duration of labeled treatment (not to exceed 48 hours postparturition) limits the need for extensive metabolic monitoring in most bovine applications.